Cinclus Pharma Holding AB
1.10
EUR
-0.03
(-2.82%)
ISIN
SE0020388577
Return %
Stock
S&P 500
1Y
-23.65
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Christer Ahlberg
- Full Time Employees
- 21
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Stockholm Sweden
- IPO Date
- Jun 20, 2024
- Website
- cincluspharma.com
- Similar Companies
- Business
- Cinclus Pharma Holding AB is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule therapeutics for the treatment of gastric acid-related gastrointestinal disorders. The company focuses on addressing unmet medical needs in patient populations that are refractory or non-responsive to conventional proton pump inhibitor (PPI) therapies. Its primary product pipeline and clinical assets include: linaprazan glurate (formerly designated X842), a proprietary, orally bioavailable prodrug belonging to the potassium-competitive acid blocker (P-CAB) class, engineered to provide rapid, potent, and sustained 24-hour gastric acid suppression for patients suffering from moderate-to-severe erosive gastroesophageal reflux disease (eGERD, Los Angeles Classification Grades C and D); therapeutic combination regimens of linaprazan glurate with antibiotics designed to optimize mucosal healing and eradicate Helicobacter pylori infections while mitigating antimicrobial resistance; and maintenance therapy regimens aimed at the long-term prevention of esophagitis relapse and symptom recurrence in chronic acid-related conditions. Founded in 2014 and headquartered in Stockholm, Sweden, the company conducts its core business operations through its wholly owned subsidiary, Cinclus Pharma AB, overseeing clinical trials, regulatory affairs, and manufacturing partnerships across Europe and the United States. In recent corporate developments, Cinclus Pharma completed an initial public offering (IPO) and listed its shares on the Nasdaq Stockholm exchange in June 2024 under the ticker symbol CINPHA. In May 2025, the company expanded its commercial footprint by entering into an exclusive strategic license and collaboration agreement with Zentiva valued at up to 220 million euros, granting Zentiva the commercialization and manufacturing rights for linaprazan glurate across the European Economic Area, the United Kingdom, and Switzerland. In its clinical operations, Cinclus Pharma completed patient treatment in its pivotal Phase III HEEALING 1 trial comparing linaprazan glurate to lansoprazole in severe eGERD, with topline data scheduled for release in late 2026, and initiated preparations for its multicenter Phase III HEEALING 2 maintenance study across European and North American clinical sites.